Two prominent gene-editing startups, Chroma Medicine and Nvelop Therapeutics, said Wednesday they will merge, forming a new company called nChroma Bio.
The merger will combine molecular machines Chroma was developing to modify genes without cutting DNA and technology Nvelop was developing to deliver DNA-modifying machinery to precise tissues in the body.
advertisement
Leadership for the combined company argued it was a natural fit. In industry parlance, it joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.